103RD GENERAL ASSEMBLY
State of Illinois
2023 and 2024
SB3701

 

Introduced 2/9/2024, by Sen. Laura Ellman

 

SYNOPSIS AS INTRODUCED:
 
720 ILCS 570/314.5
720 ILCS 570/317

    Amends the Illinois Controlled Substances Act. Provides that each prescriber or his or her designee shall document an attempt to access patient information in the Prescription Monitoring Program to assess patient access to controlled substances when providing a prescription for a Schedule II, III, IV, or V controlled substance (rather than an initial prescription for Schedule II narcotics such as opioids), except for prescriptions for oncology treatment or palliative care, or a 7-day or less supply provided by a hospital emergency department when treating an acute, traumatic medical condition. Provides that as a condition of licensure and license renewal, all prescribers holding an Illinois Controlled Substance license through the Department of Financial and Professional Regulation shall have an Illinois Prescription Monitoring Program account.


LRB103 39461 RLC 69655 b

 

 

A BILL FOR

 

SB3701LRB103 39461 RLC 69655 b

1    AN ACT concerning criminal law.
 
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
 
4    Section 5. The Illinois Controlled Substances Act is
5amended by changing Sections 314.5 and 317 as follows:
 
6    (720 ILCS 570/314.5)
7    Sec. 314.5. Medication shopping; pharmacy shopping.
8    (a) It shall be unlawful for any person knowingly or
9intentionally to fraudulently obtain or fraudulently seek to
10obtain any controlled substance or prescription for a
11controlled substance from a prescriber or dispenser while
12being supplied with any controlled substance or prescription
13for a controlled substance by another prescriber or dispenser,
14without disclosing the fact of the existing controlled
15substance or prescription for a controlled substance to the
16prescriber or dispenser from whom the subsequent controlled
17substance or prescription for a controlled substance is
18sought.
19    (b) It shall be unlawful for a person knowingly or
20intentionally to fraudulently obtain or fraudulently seek to
21obtain any controlled substance from a pharmacy while being
22supplied with any controlled substance by another pharmacy,
23without disclosing the fact of the existing controlled

 

 

SB3701- 2 -LRB103 39461 RLC 69655 b

1substance to the pharmacy from which the subsequent controlled
2substance is sought.
3    (c) A person may be in violation of Section 3.23 of the
4Illinois Food, Drug and Cosmetic Act or Section 406 of this Act
5when medication shopping or pharmacy shopping, or both.
6    (c-5) Effective January 1, 2018, each prescriber
7possessing an Illinois controlled substances license shall
8register with the Prescription Monitoring Program.
9Notwithstanding any provision of this Act to the contrary,
10beginning on and after the effective date of this amendatory
11Act of the 101st General Assembly, a licensed veterinarian
12shall be exempt from registration and prohibited from
13accessing patient information in the Prescription Monitoring
14Program. Licensed veterinarians that are existing registrants
15shall be removed from the Prescription Monitoring Program.
16Each prescriber or his or her designee shall also document an
17attempt to access patient information in the Prescription
18Monitoring Program to assess patient access to controlled
19substances when providing a an initial prescription for a
20Schedule II, III, IV, or V controlled substance narcotics such
21as opioids, except for prescriptions for oncology treatment or
22palliative care, or a 7-day or less supply provided by a
23hospital emergency department when treating an acute,
24traumatic medical condition. This attempt to access shall be
25documented in the patient's medical record. The hospital shall
26facilitate the designation of a prescriber's designee for the

 

 

SB3701- 3 -LRB103 39461 RLC 69655 b

1purpose of accessing the Prescription Monitoring Program for
2services provided at the hospital.
3    (d) When a person has been identified as having 5 or more
4prescribers or 5 or more pharmacies, or both, that do not
5utilize a common electronic file as specified in Section 20 of
6the Pharmacy Practice Act for controlled substances within the
7course of a 6-month period, the Prescription Monitoring
8Program may issue an unsolicited report to the prescribers,
9dispensers, and their designees informing them of the
10potential medication shopping. If an unsolicited report is
11issued to a prescriber or prescribers, then the report must
12also be sent to the applicable dispensing pharmacy.
13    (e) Nothing in this Section shall be construed to create a
14requirement that any prescriber, dispenser, or pharmacist
15request any patient medication disclosure, report any patient
16activity, or prescribe or refuse to prescribe or dispense any
17medications.
18    (f) This Section shall not be construed to apply to
19inpatients or residents at hospitals or other institutions or
20to institutional pharmacies.
21    (g) Any patient feedback, including grades, ratings, or
22written or verbal statements, in opposition to a clinical
23decision that the prescription of a controlled substance is
24not medically necessary shall not be the basis of any adverse
25action, evaluation, or any other type of negative
26credentialing, contracting, licensure, or employment action

 

 

SB3701- 4 -LRB103 39461 RLC 69655 b

1taken against a prescriber or dispenser.
2(Source: P.A. 101-414, eff. 8-16-19; 102-527, eff. 8-20-21.)
 
3    (720 ILCS 570/317)
4    Sec. 317. Central repository for collection of
5information.
6    (a) The Department must designate a central repository for
7the collection of information transmitted under Section 316
8and former Section 321.
9    (b) The central repository must do the following:
10        (1) Create a database for information required to be
11    transmitted under Section 316 in the form required under
12    rules adopted by the Department, including search
13    capability for the following:
14            (A) A recipient's name and address.
15            (B) A recipient's date of birth and gender.
16            (C) The national drug code number of a controlled
17        substance dispensed.
18            (D) (Blank).
19            (E) The quantities and days supply of a controlled
20        substance dispensed.
21            (F) A dispenser's Administration registration
22        number.
23            (G) A prescriber's Administration registration
24        number.
25            (H) The dates the controlled substance

 

 

SB3701- 5 -LRB103 39461 RLC 69655 b

1        prescription is filled.
2            (I) The payment type used to purchase the
3        controlled substance (i.e. Medicaid, cash, third party
4        insurance).
5            (J) The patient location code (i.e. home, nursing
6        home, outpatient, etc.) for controlled substance
7        prescriptions other than those filled at a retail
8        pharmacy.
9        (2) Provide the Department with a database maintained
10    by the central repository. The Department of Financial and
11    Professional Regulation must provide the Department with
12    electronic access to the license information of a
13    prescriber or dispenser.
14        (3) Secure the information collected by the central
15    repository and the database maintained by the central
16    repository against access by unauthorized persons.
17    All prescribers shall designate one or more medical
18specialties or fields of medical care and treatment for which
19the prescriber prescribes controlled substances when
20registering with the Prescription Monitoring Program. As a
21condition of licensure and license renewal, all prescribers
22holding an Illinois Controlled Substance license through the
23Illinois Department of Financial and Professional Regulation
24shall have an Illinois Prescription Monitoring Program
25account.
26    No fee shall be charged for access by a prescriber or

 

 

SB3701- 6 -LRB103 39461 RLC 69655 b

1dispenser.
2(Source: P.A. 103-477, eff. 8-4-23.)